JP2021526548A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021526548A5 JP2021526548A5 JP2021512351A JP2021512351A JP2021526548A5 JP 2021526548 A5 JP2021526548 A5 JP 2021526548A5 JP 2021512351 A JP2021512351 A JP 2021512351A JP 2021512351 A JP2021512351 A JP 2021512351A JP 2021526548 A5 JP2021526548 A5 JP 2021526548A5
- Authority
- JP
- Japan
- Prior art keywords
- mel
- dkla
- graph
- compare
- order
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 26
- 230000001093 anti-cancer Effects 0.000 description 16
- 230000030833 cell death Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 8
- 210000001700 mitochondrial membrane Anatomy 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 102000000412 Annexin Human genes 0.000 description 2
- 108050008874 Annexin Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000002137 anti-vascular effect Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- IKEOZQLIVHGQLJ-UHFFFAOYSA-M mitoTracker Red Chemical compound [Cl-].C1=CC(CCl)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 IKEOZQLIVHGQLJ-UHFFFAOYSA-M 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000006539 extracellular acidification Effects 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180051800 | 2018-05-04 | ||
| KR10-2018-0051800 | 2018-05-04 | ||
| PCT/KR2019/005438 WO2019212324A1 (ko) | 2018-05-04 | 2019-05-07 | 멜리틴-기반 세포사멸 유발 펩타이드로 m2 유사 종앙관련 대식세포의 표적화 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021526548A JP2021526548A (ja) | 2021-10-07 |
| JP2021526548A5 true JP2021526548A5 (enExample) | 2021-11-18 |
| JP7234349B2 JP7234349B2 (ja) | 2023-03-07 |
Family
ID=68386643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512351A Active JP7234349B2 (ja) | 2018-05-04 | 2019-05-07 | メリチンベースのアポトシース促進ペプチドペプチドでｍ２様腫瘍関連マクロファージの標的化 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11484601B2 (enExample) |
| EP (1) | EP3789041A4 (enExample) |
| JP (1) | JP7234349B2 (enExample) |
| KR (1) | KR102250412B1 (enExample) |
| CN (1) | CN112533640B (enExample) |
| AU (1) | AU2019264092B2 (enExample) |
| CA (1) | CA3099434C (enExample) |
| WO (1) | WO2019212324A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240009269A1 (en) * | 2020-11-20 | 2024-01-11 | The Johns Hopkins University | Membrane-active peptides and methods for reversible blood- brain barrier opening |
| US20220354957A1 (en) * | 2021-05-07 | 2022-11-10 | Twinpig Biolab, Inc. | Peptides targeting macrophages, and conjugates, compositions, and uses thereof |
| CN113336828B (zh) * | 2021-06-30 | 2022-03-25 | 中国海洋大学 | 抗菌肽yhx-3及其组合物和应用 |
| CN114437193A (zh) * | 2022-01-29 | 2022-05-06 | 陕西未来多肽生物科技有限公司 | 一种金-蜂毒肽纳米杂化物及其应用 |
| EP4512410A1 (en) * | 2022-04-07 | 2025-02-26 | Twinpig Biolab, Inc. | Novel-peptide-based anticancer immunotherapeutic agent |
| WO2023204329A1 (ko) * | 2022-04-22 | 2023-10-26 | 트윈피그바이오랩(주) | 신규 펩타이드 기반 면역항암제 |
| CN115317622B (zh) * | 2022-08-12 | 2025-08-22 | 青岛科技大学 | 一种抗肿瘤多肽偶联药物的制备及其应用 |
| CN116589555B (zh) * | 2023-03-31 | 2024-02-06 | 广东医科大学 | 一种细胞穿梭肽及其应用 |
| CN119896743B (zh) * | 2023-10-26 | 2025-09-26 | 华南理工大学 | 一种基质金属蛋白酶响应的多功能仿生铁蛋白纳米材料及其制备方法与应用 |
| KR20250091126A (ko) * | 2023-12-12 | 2025-06-20 | 트윈피그바이오랩(주) | 신규 펩타이드를 유효성분으로 포함하는 항암제와의 병용투여를 위한 항암 조성물 |
| CN120053399A (zh) * | 2025-02-27 | 2025-05-30 | 滁州学院 | 一种蜂毒肽靶向制剂及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5135736A (en) * | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| AUPQ014799A0 (en) | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
| WO2005049647A2 (en) | 2003-11-05 | 2005-06-02 | Pevion Biotech Ltd. | Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens |
| CA2745499A1 (en) * | 2008-12-05 | 2010-06-10 | Angiochem Inc. | Peptide therapeutic conjugates and uses thereof |
| KR20110117788A (ko) | 2010-04-22 | 2011-10-28 | 대한민국(농촌진흥청장) | 멜리틴을 포함하는 섬유아세포-유사-활막세포의 활성을 억제하는 조성물 |
| KR20110117789A (ko) | 2010-04-22 | 2011-10-28 | 대한민국(농촌진흥청장) | 멜리틴을 함유하는 동맥경화 치료용 조성물 |
| KR101695792B1 (ko) | 2014-09-04 | 2017-01-12 | 디오셀 주식회사 | 신규 세포막 투과 펩티드 및 생리활성 물질 전달체로서의 그의 용도 |
| KR101935095B1 (ko) * | 2015-07-31 | 2019-01-04 | 이화여자대학교 산학협력단 | 신규한 세포투과성 펩타이드 |
| CN106699896B (zh) * | 2016-12-05 | 2020-06-05 | 华中科技大学同济医学院附属协和医院 | 一种可自组装成水凝胶的肿瘤杀伤性多肽及其应用 |
| KR102073273B1 (ko) | 2017-08-23 | 2020-03-02 | (주) 레느스랩 | 멜리틴을 포함하는 m2형 종양관련 대식세포 제거용 조성물 |
-
2019
- 2019-05-07 KR KR1020190053334A patent/KR102250412B1/ko active Active
- 2019-05-07 US US17/052,943 patent/US11484601B2/en active Active
- 2019-05-07 EP EP19796650.0A patent/EP3789041A4/en active Pending
- 2019-05-07 CN CN201980030270.8A patent/CN112533640B/zh active Active
- 2019-05-07 JP JP2021512351A patent/JP7234349B2/ja active Active
- 2019-05-07 WO PCT/KR2019/005438 patent/WO2019212324A1/ko not_active Ceased
- 2019-05-07 CA CA3099434A patent/CA3099434C/en active Active
- 2019-05-07 AU AU2019264092A patent/AU2019264092B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021526548A5 (enExample) | ||
| Multhoff et al. | Hypoxia compromises anti-cancer immune responses | |
| Lison | Cobalt | |
| Yu et al. | The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer | |
| JP2023120393A5 (enExample) | ||
| Acar et al. | Tumor-infiltrating lymphocytes (TIL), tertiary lymphoid structures (TLS), and expression of PD-1, TIM-3, LAG-3 on TIL in invasive and in situ ductal breast carcinomas and their relationship with prognostic factors | |
| Fu et al. | Hirsutella sinensis inhibits lewis lung cancer via tumor microenvironment effector T cells in mice | |
| Liu et al. | Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study | |
| López-Gómez et al. | Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives | |
| Li et al. | 1589eP Immune rechallenge as second-line treatment after first-line immunotherapy failure in advanced gastric cancer: A single-center real-world study | |
| KUMARI et al. | EFFECT OF RAMUCIRUMAB ON PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN CONVENTIONAL DRUG RESISTANT OR METASTATIC NON-SQUAMOUS VARIANT OF NON-SMALL CELL LUNG CANCERS: A PILOT STUDY | |
| MEGUMI et al. | The Role of Tumor-associated Macrophages in Colorectal Peritoneal Metastasis in Mice | |
| Chayangsu | Clinicopathological characteristics and prognostic factors of malignant melanoma: A retrospective analysis of a 12-year study | |
| Jalalizadeh et al. | TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) POTENTIATES THE EFFECT OF BACILLUS CALMETTE-GUÉRIN (BCG) IN UROTHELIAL CARCINOMA MODEL: MP83-09 | |
| CN109223746B (zh) | 一种紫草茸酸用于逆转卵巢癌对紫杉醇耐药性的用途 | |
| Wu et al. | 107P Anlotinib plus chemotherapy as first-line (1L) treatment in gastrointestinal cancer patients with unresectable liver metastases | |
| Ghazi et al. | The Effect of IL-6 Expression on the Behavior of Oral Squamous Cell Carcinoma Cells (An immunohistochemical Study) | |
| Samejima et al. | P1. 05-018 Prognostic Impact of Tumor Shadow Disappearance Rate in Patients with Clinical IA Lung Adenocarcinoma | |
| Raduc et al. | Assessing the value of pemigatinib versus gemcitabine/cisplatin therapy in patients with cholangiocarcinoma: A cost-effectiveness analysis. | |
| de la Cruz et al. | 972 A Functional Pharmacogenetic Screen in Non-small Cell Lung Adenocarcinoma | |
| Hozak et al. | Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study | |
| Bacalbasa et al. | The impact of preoperative platelet count in vulvar cancer patients | |
| Buchanich et al. | Comparison of mortality rates between Appalachian coal mining counties with non-coal mining | |
| Orlandi et al. | Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo)+ bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups | |
| Masutomi et al. | Immunohistochemical analysis of CD133/44 expression in surgical specimens of squamous cell carcinoma of the esophagus after neoadjuvant chemotherapy |